MCID: NSL008
MIFTS: 33

Nasal Cavity Cancer malady

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Nasal Cavity Cancer

Aliases & Descriptions for Nasal Cavity Cancer:

Name: Nasal Cavity Cancer 12 14
Nasal Cavity Carcinoma 12 14 69
Neoplasm of Nasal Cavity 12 69
Nasal Cavity Neoplasm 12 14
Malignant Neoplasm of Nasal Cavities 12
Malignant Tumor of the Nasal Cavity 12
Malignant Neoplasm of Nasal Cavity 69
Carcinoma of Nasal Cavity 12
Tumor of the Nasal Cavity 12
Cancer of Nasal Cavity 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10811 DOID:4931 DOID:9310
ICD10 33 C30.0
ICD9CM 35 160.0

Summaries for Nasal Cavity Cancer

Disease Ontology : 12 A nasal cavity cancer that_has material basis in epithelial cells.

MalaCards based summary : Nasal Cavity Cancer, also known as nasal cavity carcinoma, is related to nasal cavity carcinoma in situ and nasal cavity cancer, childhood, and has symptoms including pain and rhinorrhea. An important gene associated with Nasal Cavity Cancer is CXCL11 (C-X-C Motif Chemokine Ligand 11). The drugs Menthol and Nicotine have been mentioned in the context of this disorder. Related phenotypes are embryo and growth/size/body region

Related Diseases for Nasal Cavity Cancer

Graphical network of the top 20 diseases related to Nasal Cavity Cancer:



Diseases related to Nasal Cavity Cancer

Symptoms & Phenotypes for Nasal Cavity Cancer

UMLS symptoms related to Nasal Cavity Cancer:


pain, rhinorrhea

MGI Mouse Phenotypes related to Nasal Cavity Cancer:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 embryo MP:0005380 9.46 ANKRD11 CDX2 KRT8 SLC25A19
2 growth/size/body region MP:0005378 9.35 ANKRD11 CDX2 KRT8 PDYN SLC25A19
3 homeostasis/metabolism MP:0005376 9.02 ANKRD11 CDX2 KRT8 PDYN SLC25A19

Drugs & Therapeutics for Nasal Cavity Cancer

Drugs for Nasal Cavity Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 413)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Menthol Approved Phase 4,Phase 1 2216-51-5 16666
2
Nicotine Approved Phase 4 54-11-5 942 89594
3
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3 437-38-7 3345
5
Cefazolin Approved Phase 4 25953-19-9 656510 33255
6
Cefdinir Approved Phase 4 91832-40-5 6915944
7
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
8
Sulfamethoxazole Approved Phase 4 723-46-6 5329
9
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
10
Cyclizine Approved Phase 4 82-92-8 6726
11
Haloperidol Approved Phase 4 52-86-8 3559
12
Heroin Approved, Illicit Phase 4 561-27-3 5462328
13
Methotrimeprazine Approved Phase 4 60-99-1 72287
14
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
15
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
16
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3 76-42-6 5284603
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
18
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
19 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
20 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
21 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
22 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Hemostatics Phase 4
24 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
25 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
26 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1
27 Antiparasitic Agents Phase 4,Phase 1
28 Antiprotozoal Agents Phase 4,Phase 1
29 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3
30 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
31 Central Nervous System Stimulants Phase 4,Phase 3
32 Cholinergic Agents Phase 4,Phase 2,Phase 3
33 Nicotinic Agonists Phase 4
34 Clindamycin palmitate Phase 4
35 Clindamycin phosphate Phase 4
36 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1
37 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
38 Adjuvants, Anesthesia Phase 4,Phase 3
39 Analgesics, Opioid Phase 4,Phase 3
40 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1
41 Anesthetics, General Phase 4,Phase 3
42 Anesthetics, Intravenous Phase 4,Phase 3
43 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
44 Hypnotics and Sedatives Phase 4,Phase 2
45 Narcotics Phase 4,Phase 3
46 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
47 Psychotropic Drugs Phase 4,Phase 3,Phase 2
48 Antimalarials Phase 4,Phase 1
49 Antitubercular Agents Phase 4
50 cefuroxime axetil Phase 4

Interventional clinical trials:

(show top 50) (show all 347)
id Name Status NCT ID Phase
1 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4
2 Karydakis Procedure Versus Excision With Healing by Secondary Intention (EHSI) in Sacrococcygeal Pilonidal Sinus Completed NCT00716937 Phase 4
3 Cavernous Sinus Dissection and Bleeding in Meningiomas Recruiting NCT02863484 Phase 4
4 Improvement of Outcomes in Draf III/Endoscopic Modified Lothrop Procedure Recruiting NCT02981017 Phase 4
5 Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4
6 Nasal Fentanyl and Buccal Midazolam for Dying Patients Recruiting NCT02009306 Phase 4
7 Interest in the Use of Dressings With Honey for Wound Healing After Excision of Pilonidal Cyst Recruiting NCT02485860 Phase 4
8 Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE) Unknown status NCT00117572 Phase 3
9 Evaluation of 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Cancer. Unknown status NCT01124409 Phase 3
10 S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer Unknown status NCT00336947 Phase 3
11 Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00002659 Phase 3
12 Nasal Packing as a Drug Delivery System Postoperatively in Chronic Sinusitis With Polyposis Unknown status NCT01197612 Phase 3
13 Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Completed NCT00008398 Phase 3
14 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3
15 Laryngeal Preservation in Pyriform Sinus Carcinoma Completed NCT00770393 Phase 2, Phase 3
16 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
17 Radiation Therapy in Treating Patients With Head and Neck Cancer Completed NCT00021125 Phase 3
18 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
19 Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002888 Phase 3
20 Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00003809 Phase 3
21 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3
22 Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002476 Phase 3
23 Surgery and Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer That Can Be Removed During Surgery Completed NCT00003576 Phase 3
24 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3
25 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3
26 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003592 Phase 3
27 Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Exten Completed NCT01622569 Phase 3
28 Mid-line Excision Versus Karydakis Operation for Pilonidal Sinus Completed NCT00412659 Phase 2, Phase 3
29 Biological Mesh Closure of the Pelvic Floor After Extralevator Abdomino Perineal Resection for Rectal Cancer Completed NCT01927497 Phase 3
30 A Trial on Clinical Efficacy of 1% Versus 2% Lignocaine in Cough Suppression and Pain Relief in Patients Undergoing Flexible Bronchoscopy Completed NCT01955824 Phase 2, Phase 3
31 A Study of Lebrikizumab in Participants With Uncontrolled Asthma on Inhaled Corticosteroids and a Second Controller Medication Completed NCT01868061 Phase 3
32 Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy Recruiting NCT02480114 Phase 3
33 Resource Sparing Curative Radiotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck: The HYPNO Trial Recruiting NCT02765503 Phase 3
34 Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis With Polyposis Nasi Recruiting NCT01946711 Phase 3
35 Chemo-radiotherapy Versus Radiotherapy in the Treatment of Salivary Glands and Nasal Tumors Recruiting NCT02998385 Phase 3
36 Collagen Implant Compared to Gluteus Maximus Flap for Reconstruction of Pelvic Floor After ELAPE/EAPE in Rectal Cancer Recruiting NCT01347697 Phase 3
37 Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors Recruiting NCT03067181 Phase 3
38 Safety Study of Totally Laparoscopic Resection With Natural Orifice Specimen Extraction (NOSE) for Rectosigmoid Cancer Recruiting NCT02635503 Phase 3
39 Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors Recruiting NCT02375204 Phase 3
40 A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Pegylated (PEG) L-Asparaginase Recruiting NCT02369653 Phase 3
41 Infiltration in the Region of the Palatine Ganglion Spheno by Ropivacaine on Postoperative Pain Recruiting NCT02821169 Phase 3
42 Acupuncture in Treating Dry Mouth Caused By Radiation Therapy in Patients With Head and Neck Cancer Active, not recruiting NCT01141231 Phase 3
43 Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT00588770 Phase 3
44 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Active, not recruiting NCT01156142 Phase 3
45 Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors Active, not recruiting NCT00053352 Phase 3
46 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3
47 Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck Unknown status NCT00003182 Phase 1, Phase 2
48 Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer Unknown status NCT00003251 Phase 1, Phase 2
49 Surgery, Radiation Therapy, and Combination Chemotherapy in Treating Patients With Recurrent Head and Neck Cancer Unknown status NCT00003777 Phase 2
50 Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00003327 Phase 2

Search NIH Clinical Center for Nasal Cavity Cancer

Genetic Tests for Nasal Cavity Cancer

Anatomical Context for Nasal Cavity Cancer

Publications for Nasal Cavity Cancer

Articles related to Nasal Cavity Cancer:

id Title Authors Year
1
(P092) definitive chemoradiotherapy or radiotherapy for unresectable, very locally advanced, or medically inoperable paranasal sinus and nasal cavity cancer. ( 25930909 )
2015
2
Paranasal Sinus and Nasal Cavity Cancer Treatment (PDQAr): Health Professional Version ( 26425762 )
2002
3
Paranasal Sinus and Nasal Cavity Cancer Treatment (PDQAr): Patient Version ( 27559600 )
2002
4
Paranasal Sinus and Nasal Cavity Cancer Treatment (PDQAr): Health Professional Version ( 26389272 )
2002
5
Paranasal Sinus and Nasal Cavity Cancer Treatment (PDQAr): Patient Version ( 27195380 )
2002
6
Paranasal Sinus and Nasal Cavity Cancer Treatment (PDQAr): Patient Version ( 26389439 )
2002
7
Nasal obstruction portending nasal cavity cancer. ( 2599810 )
1989
8
Paranasal sinuses and nasal cavity cancer: different radiotherapeutic options, results and late damages. ( 3810867 )
1986

Variations for Nasal Cavity Cancer

Expression for Nasal Cavity Cancer

Search GEO for disease gene expression data for Nasal Cavity Cancer.

Pathways for Nasal Cavity Cancer

GO Terms for Nasal Cavity Cancer

Sources for Nasal Cavity Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....